Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2015

Giant Cell Tumor of the Larynx Treated by Surgery
and Adjuvant Denosumab: Case Report and
Review of the Literature
A. E. Yancoskie
Northwell Health

D. K. Frank
Hofstra Northwell School of Medicine

J. E. Fantasia
Hofstra Northwell School of Medicine

S. Savona
Hofstra Northwell School of Medicine

N. Eiseler
Northwell Health
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Medical Molecular Biology Commons, Oral Biology and Oral Pathology Commons,
Otolaryngology Commons, and the Pathology Commons
Recommended Citation
Yancoskie A, Frank D, Fantasia J, Savona S, Eiseler N, Reder I, Kahn L. Giant Cell Tumor of the Larynx Treated by Surgery and
Adjuvant Denosumab: Case Report and Review of the Literature. . 2015 Jan 01; 9(4):Article 628 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/628. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.

Authors

A. E. Yancoskie, D. K. Frank, J. E. Fantasia, S. Savona, N. Eiseler, I. Reder, and L. B. Kahn

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/628

Head and Neck Pathol (2015) 9:447–452
DOI 10.1007/s12105-015-0622-4

ORIGINAL PAPER

Giant Cell Tumor of the Larynx Treated by Surgery
and Adjuvant Denosumab: Case Report and Review
of the Literature
Aaron E. Yancoskie1 • Douglas K. Frank2 • John E. Fantasia1 • Steven Savona3
Nicole Eiseler4 • Ilan Reder5 • Leonard B. Kahn5

•

Received: 4 February 2015 / Accepted: 5 March 2015 / Published online: 8 March 2015
Ó Springer Science+Business Media New York 2015

Abstract Giant cell tumor of the larynx (GCTL) is a rare
entity; only 34 cases have been reported in the literature.
We report a case of GCTL in a 46 year-old male presenting
clinical, radiographic, histological and therapeutic features.
Previously reported cases are also reviewed.

[1, 2]. GCT of bone is a benign neoplasm with a 25 % rate of
recurrence [2]. Six to ten percent of GCTs exhibit malignant
features manifesting as high-grade sarcoma occurring at the
site of a prior benign GCT or as a sarcoma in juxtaposition to
the GCT [2]. No such association has been recorded in the
reported cases of GCTL [2, 3].

Keywords Giant cell  Denosumab  Head and neck
surgery  Larynx

Case Report
Introduction
Giant cell tumor of the larynx (GCTL) is a rare entity with
34 cases reported to date. Giant cell tumor (GCT) occurs
most frequently in the epiphysis of the long bones of patients
in their third decade and has a slight female predilection
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A 46-year-old male was referred to the division of head
and neck surgery for evaluation of a left neck mass causing
dyspnea. He was otherwise healthy. He denied prior or
current tobacco use. A contrast enhanced computerized
tomographic scan showed an expansile destructive lesion
epicentered on the left thyroid ala with invasion of the
overlying strap muscles. The left glottic and supraglottic
tissues were involved (Fig. 1). The patient was taken to the
operating room for tracheotomy to protect the airway and a
subsequent laryngoscopic biopsy was performed. The
procedure was tolerated well by the patient and he was
discharged without event. Histopathologic review of the
material obtained by biopsy revealed only normal laryngeal mucosa. Ten days later the patient underwent an ultrasound-guided trans-cervical core biopsy of the mass.
The histopathologic features were interpreted as a giant
cell lesion consistent with either a GCT or a giant cell
granuloma (GCG) (Fig. 2). Blood chemistry studies
demonstrated normal levels of serum calcium. A left
hemilaryngectomy with frontolateral extension was planned with the intent of laryngeal preservation. Remaining
foci of tumor would be treated with denosumab. Due to
strap muscle infiltration by tumor, a supraclavicular pedicle flap was used for reconstruction of the hemilaryngeal
defect. Gross examination of the resected specimen
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Fig. 1 Computed tomography scan demonstrating an expansile
destructive lesion epicentered on the left thyroid ala with invasion
of the overlying strap muscles and involvement of the left glottic and
supraglottic tissues

Fig. 2 Histopathology hematoxcylin and eosin 9200 original magnification. Core biopsy specimen showing giant cells, a mononuclear
population and extravasated erythrocytes

revealed a 4.5 9 4.0 9 3.5 cm nodular mass composed of
white-tan homogenous, rubbery tissue with a central
hemorrhagic focus (Fig. 3). Microscopic examination revealed a cellular neoplasm composed of numerous uniformly distributed osteoclast-like giant cells separated by
uniform mononuclear cells whose nuclei resembled those
of the giant cells (Fig. 4). The tumor had breached the
confines of the bone and cartilage of the thyroid ala and
extended into the adjacent soft tissue. Scattered reactive
woven bone and occasional mitoses were noted. Microscopic foci of tumor were identified at the margins. Based
upon the uniform distribution of the giant cells, a diagnosis
of GCT was made. The patient is currently being treated
with denosumab.
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Fig. 3 Gross specimen. Nodular mass measuring 4.5 9 4.0 9
3.5 cm composed of white-tan homogenous, rubbery tissue with a
central hemorrhagic focus

Fig. 4 Histopathology hematoxcylin and eosin 9400 original magnification. Resection specimen demonstrating numerous uniformly
distributed osteoclast-like giant cells separated by mononuclear cells
in a vascular stroma

Discussion and Review of the Literature
GCT most commonly occurs in the epiphysis of the long
bones, having a predilection for females in their third
decade [1, 2]. These tumors are essentially benign, but may
be locally aggressive [2]. Significant rates of recurrence
have been reported [2]. Histologically, GCTs are composed
of a mixture of multinucleated giant cells and mononuclear
cells in a fibroblast rich, loose, hemorrhagic, vascular
stroma [2]. The nuclei of the giant cells are strikingly
similar to those of the monuclear cells [2]. Lau et al. [4]
demonstrated that the mononuclear component of GCT
expressed alkaline phosphatase and receptor activator of
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Table 1 Cases of giant cell tumor of the larynx
Case

Year

Author

Gender

Age (years)

Location

Laterality

Size (cm)

1

1940

Wessely

Male

51

Cricoid

2

1951

Federova

Male

35

Thyroid

3

1952

Wagemann

Male

40

Cricoid

4

1958

Perrino

Male

32

Cricoid

5

1966

Kaliteevskii

Male

52

Thyroid

6

1968

Pohl

Male

50

Thyroid

7

1969

Kohn

Male

50

Epiglottis

8

1971

Rudert

Male

53

Thyroid

9

1973

Goto

Male

47

Thyroid

10

1975

Ribari

Male

35

Cricoid

11
12

1974
1974

Kotarba
A. Coyas

Male
Male

60
67

Epiglottis
Vocal cord

13

1976

Kubo

Male

40

Cricoid

14

1976

John Hall-Jones

Male

26

Thyroid

15

1979

Tsybyrne

Male

34

Thyroid

16

1988

Borghese

Male

28

Thyroid

17

1993

Murrell

Male

42

Thyroid

Left

18

1994

P. C. Martin

Male

23

Thyroid

Right

4

19

1995

D. M. Thomas

Female

56

Cricoid

Bilateral

2

20

1996

Jochen A. Werner

Male

35

Thyroid

21

2000

Hinni

Male

31

Thyroid

Left

4

22

2001

Wieneke

Male

26

Thyroid

Right

4.2*

23

2001

Wieneke

Male

37

Thyroid

Left

4.2*

24

2001

Wieneke

Male

37

Cricoid

Right

4.2*

25

2001

Wieneke

Male

40

Thyroid

26

2001

Wieneke

Male

44

Thyroid

Left

4.2*

27
28

2001
2001

Wieneke
Wieneke

Female
Male

53
57

Thyroid
Cricoid

Bilateral

4.2*
4.2*

29

2001

Wieneke

Female

62

Thyroid

Left

4.2*

30

2003

Wong

Male

49

Thyroid

Left

4

31

2006

Nishimura

Male

31

Thyroid

Right

4

32

2011

Rochanawutanon

Male

29

Cricoid ST

Left

4

33

2013

C. de la Fouchardiere

Male

38

Thyroid

Right

4

34

2014

Nota

Male

59

Thyroid

Left

3

35

2015

Current case

Male

46

Thyroid

Left

4.5

‘‘Walnut’’
Right

‘‘Hazel nut’’ and ‘‘chick pea’’

Right

5.5

4.8

4.2*

* Cases averaged by author

nuclear factor kappa-B ligand (RANKL), markers of osteoblast lineage, while the multinucleate component expressed tartrate-resistant acid phosphatase and vitronectin
receptor, markers of osteoclastic lineage.
The head and neck region is an infrequent site for GCTs,
which tend to involve the sphenoid, ethmoid and temporal
bones [3]. The first case of GCTL was reported by Wesely
in 1940 [5–8]. Since then a total of 33 additional cases have
been published [3, 5–18].
There is a strong male preponderance (8.5:1) with an
average age at diagnosis of 42 years [3, 5–18]. Of the

laryngeal structures, the thyroid cartilage is the most
common site of origin (21, 60 %), followed by the cricoid
cartilage (9, 26 %), the epiglottis (2, 6 %) and the soft
tissues of the larynx (2, 6 %) [3, 5–18]. The location of one
case was not specified [5–8] (Table 1).
The most commonly reported findings on physical exam
were dysphonia (16, 47 %) and a palpable neck mass (15,
44 %). These were followed by respiratory difficulty (6,
18 %) and dysphagia (5, 15 %). Other less common findings included sore throat and changes in vocal cord mobility. Four authors reported normal laboratory values for
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serum calcium and three reported normal alkaline phosphatase levels, two of which also reported normal levels of
parathyroid hormone. In eleven cases a history of tobacco
use was elicited and was denied by all [3, 5–18].
The treatment modality was described in 32 of the 34
cases [3, 5–18]. The majority of cases were treated by surgery alone (19, 56 %), ranging from local excision to total
laryngectomy. Eight cases were treated by surgery and radiation (24 %), three by radiation alone (9 %) and one case
by surgery, radiation and chemo therapy (3 %) [3, 5–18].
Derbel et al. [18] recently reported the use of denosumab
following surgery in treating a single case of GCTL (3 %).
In seventeen cases at least one measurement of the tumor was reported clinically, radiographically or by gross
examination [3, 5–8, 10, 13, 14, 16–18]. The average dimension was 4.0 cm. The microscopic descriptions were
those of classic GCTs consisting of multinucleated giant
cells and mononuclear cells with a stroma composed of
fibroblasts, marked vascularity, and hemorrhagic foci.
While two authors reported thyroid gland displacement by
the tumor [10, 18], there were no reports of infiltration of
the thyroid gland. Thirty-one cases involved the cartilaginous structures of the larynx, two cases occurred in the soft
tissues and one case occurred in an unspecified location [3,
5–18]. It was reported that bone was identified in the microscopic specimens of twelve cases [5–9, 11–14, 16, 18].
This is of interest as aberrations in the maturation and
ossification process of cartilaginous structures has been
suggested as a possible etiologic factor in the development
of giant cell lesions [13]. Mitotic activity was reported in
seventeen cases [3, 4, 7, 8, 10, 11, 14, 15, 17, 19] but only
one of these commented on pleomorphism [9].
A total of 23 cases included follow up information,
which ranged from 3 months to 25 years, with an average
of 5 years 9 months [3, 4, 7–10, 12–15, 17, 18]. In 22 of
these cases, no recurrence or metastasis was reported [3, 4,
7, 8, 10, 12–15, 17, 18]. The case presented by Coyas et al.
[9] was reported to have both recurred and metastasized.
The initial presentation was that of a soft tissue mass on the
right true vocal cord. Radiographic studies showed the
tumor to be restricted to the soft tissues of the larynx with
no cartilaginous involvement. Following excision, the tumor recurred twice. The patient subsequently underwent
radiation therapy after which a tumor of the skin overlying
the initial surgical bed developed. The tumor was excised
and showed the same giant cell histology as the previously
excised lesions. The authors considered this to represent
local metastasis [9]. It is likely that the multiple recurrences were related to incomplete excision, rather than
metastatic disease [13]. Rochanawutanon et al. [17] also
reported of a case of GCTL of the soft tissues. Their case
was initially treated by resection and showed no recurrence
or metastasis at 11 years [18].
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Weineke et al. [3] suggest that GCTL appears to have a
less aggressive behavior than its long bone counterpart.
Our review of the literature would seem to confirm this
view. This, however, may be a reflection of the small
number of cases and limited follow-up.
The differential diagnosis for lesions containing numerous osteoclast-like giant cells includes GCT, GCG
(also referred to as giant cell reparative granuloma), foreign body giant cell reaction, brown tumor of hyperparathyroidism and giant cell-rich osteosarcoma [3, 13]. In
the case of a foreign body giant cell reaction, the distribution of the giant cells would be less regular, their number
fewer and they would aggregate around the foreign material. The brown tumor of hyperparathyroidism can appear
grossly and microscopically similar to GCT and GCG [20].
It is therefore essential that the patient be evaluated to rule
out hyperparathyroidism. In addition to the presence of
giant cells, giant cell-rich osteosarcoma should demonstrate the deposition of osteoid in irregular sheets or in a
lace-like distribution [22]. Additionally, the osteogenic
cells should show some degree of nuclear pleomorphism
[22].
As documented in the differential diagnosis of the core
biopsy specimen from our patient, the distinction of GCT
from GCG can present a challenge to the surgical pathologist. GCG of the head and neck most commonly occurs in
the mandible as a central lesion, is more common in females than males and has a predilection for those under
30 years [20]. Both lesions show the presence of numerous
giant cells and mononuclear cells, and a stroma rich in
fibroblasts and vasculature [3, 19, 20]. GCTs tend to exhibit more uniform distribution of the giant cells as well as
giant cells that possess a greater number of nuclei (often
exceeding 20) [3]. Thomas et al. [14] reported a giant cell
lesion of the larynx that they diagnosed as giant cell
reparative granuloma. In their description of the histopathology they mention that areas of the lesion demonstrated features of GCT but the more irregular distribution
of giant cells was consistent with giant cell reparative
granuloma [14]. Similarly, our case showed somewhat of a
bi-phasic pattern.
At least two views concerning the nature of giant cell
lesions exist. One posits that GCT and GCG are two distinct entities. GCG occurs in a younger age group (20 vs.
30) and has a lower rate of recurrence (13–35 vs. 60 %)
[23]. Furthermore, only isolated cases of metastasis or
sarcomatous transformation have been reported with GCG,
as opposed to the 6–10 % rate of sarcomatous transformation and 2 % rate of metastasis seen in GCT [23, 24].
Waldron and Shafer [19] point out that these differences
may be related to earlier clinical detection and diagnosis in
the gnathic locations. They view GCT and GCG as a single
entity [19, 20]. Liu et al. [21] provide support for this
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viewpoint by demonstrating that receptor activator of nuclear factor kappa-B (RANK) and RANKL (markers of
osteoclastic and osteoblastic differentiation) are expressed
on lesional cells of both GCT and GCG. Research by
Gomes and colleagues indicate these two diseases possess
separate molecular profiles. Mutation of the H3F3A gene
has been reported in 90 % of GCTs. Gomes et al. [25]
evaluated nine cases of GCG for this mutation and found
all cases to be negative further supporting the theory that
the two entities may indeed be distinct.
Treatment of GCT is an area of continued debate [26].
Localized control can often be achieved by wide resection
[26]. Based on our review, wide local resection is a sufficient surgery for GCTL [3, 5–18]. However, this can be
problematic in cases where resection may leave a functional deficit or encroach upon vital structures. Some have
advocated the use of radiation, but post-radiation sarcoma
is of concern [7, 16, 18]. An ideal treatment for GCT has
yet to be identified [26, 27].
Presently a multinational clinical trial is being conducted to examine the efficacy of denosumab in the treatment of GCT of bone [27]. Denosumab is a fully-human
monoclonal antibody that binds RANKL and inhibits
RANK-RANKL interactions [28]. RANK is expressed on
the surface of osteoclast precursors. In order to differentiate
into osteoclasts, their RANK receptors must interact with
RANKL that is expressed on osteoblasts. It is theorized that
this interaction is prevented by the presence of denosumab
[4, 27, 28]. The most recent data from this trial suggests
that denosumab is a viable alternative therapy for GCT of
bone when function-sparing surgery is not felt to be possible. While this treatment appears to be effective, 9 % of
patients have developed serious adverse side effects in a
phase two study. These included hypocalcemia (5 %), osteonecrosis of the jaw (1 %, two of three cases resolved),
serious infection (2 %), and a new primary malignancy
(1 %) [27]. The use of denosumab should be considered
with attention to the renal function of the patient since
renal dysfunction increases the risk of hypocalcaemia.
Additionally, there have been reports of atypical femoral
fractures seen in patients receiving denosumab therapy
[29]. However, no causal relationship is known, nor has
fracture been documented as a side effect of the medication
[29].
Derbel et al. [18] reported their experience in treating a
single case of laryngeal GCT with denosumab. Following
denosumab treatment, the decision was still made to resect
residual tumor by total laryngectomy. Histopathological
review of the resection specimen showed a complete absence of giant cells with ossification of the tumor bed [18].
Denosumab therapy was initiated for our patient 2 months
following surgery. The patient had no signs of disease recurrence at their 8 months post-surgery follow-up visit.
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Conclusions
GCTL is a rare entity with only 34 cases reported in the
literature. It has a marked predilection for adult males and
most commonly involves the thyroid cartilage. While it
appears to respond well to surgical resection, future nonsurgical therapies may be considered. We have presented
an additional case treated by surgery with adjuvant
denosumab treatment, reviewed the literature and discussed the clinical and epidemiological features as well as
the differential diagnosis and summary of various treatment modalities.
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